Expression of antigen CD95(Fas/APO-1) mediating apoptosis in hemoblastosesusing monoclonal antibodies ICO-160.

Expression of the antigen CD95(Fas/APO-1) was studied on peripheral blood c ells of 56 B-CLL patients, bone marrow cells of 46 MM patients, peripheral blood blast cells of 50 CML patients in blast crisis, 9 patients in acceler ation. In chronic phase of CML we analysed antigen CD95 expression on granu locytes of peripheral blood in 48 patients and in the lymphoid gate in 29 n ewly diagnosed of patients in chronic phase of CML. The expression was also studied on the bone marrow cells of 47 MDS patients, an blast cells of per ipheral blood and bone marrow of 15 AML patients, on blast cells of bone ma rrow of 38 ALL children. In B-CLL patients the expression of the antigen CD 95 was detected in 25% of cases on 41.5 +/- 3.8% of peripheral blood antige n positive cells. In MM the antigen was expressed in 56.5% on 37.2 +/- 2.8% of antigen positive cells. In CML the expression is registered on small nu mber of blast cells in chronic phase, is present on blast cells in accelera tion and in blast crisis. In the granulocytic gate, the expression was not found. Survival of MDS and ALL patients whose bone marrow cells express ant igen CD95 indicates that the presence of CD95 antigen is prognostically fav ourable.